US Patent

US10695336 — Dose-dumping resistant controlled release dosage form

Method of Use · Assigned to Osmotica Kereskedelmi es Szolgaltato KFT · Expires 2037-02-03 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a controlled release dosage form of methylphenidate hydrochloride that resists dose dumping when exposed to alcohol.

USPTO Abstract

The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4032 — methylphenidate-hydrochloride
U-4032 — methylphenidate-hydrochloride
U-4032 — methylphenidate-hydrochloride
U-4032 — methylphenidate-hydrochloride
U-4032 — methylphenidate-hydrochloride
U-4032 — methylphenidate-hydrochloride
U-4032 — methylphenidate-hydrochloride

Patent Metadata

Patent number
US10695336
Jurisdiction
US
Classification
Method of Use
Expires
2037-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Osmotica Kereskedelmi es Szolgaltato KFT
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.